Matthew J. Rioth

1.8k total citations
28 papers, 717 citations indexed

About

Matthew J. Rioth is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, Matthew J. Rioth has authored 28 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Immunology and 9 papers in Cancer Research. Recurrent topics in Matthew J. Rioth's work include Immunotherapy and Immune Responses (7 papers), Cancer Genomics and Diagnostics (6 papers) and Ocular Oncology and Treatments (6 papers). Matthew J. Rioth is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Cancer Genomics and Diagnostics (6 papers) and Ocular Oncology and Treatments (6 papers). Matthew J. Rioth collaborates with scholars based in United States, United Kingdom and Canada. Matthew J. Rioth's co-authors include Sandra Ryeom, Ryan C. Lynch, Douglas B. Johnson, Leora Horn, Andrea I. McClatchey, Karen Cichowski, Bryan W. Johnson, Annie W. Chan, Elizabeth E. Reczek and Sybil M. Genther Williams and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Matthew J. Rioth

28 papers receiving 710 citations

Peers

Countries citing papers authored by Matthew J. Rioth

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Rioth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Rioth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Rioth more than expected).

Fields of papers citing papers by Matthew J. Rioth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Rioth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Rioth. The network helps show where Matthew J. Rioth may publish in the future.

Co-authorship network of co-authors of Matthew J. Rioth

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Rioth. A scholar is included among the top collaborators of Matthew J. Rioth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Rioth. Matthew J. Rioth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma 2024 ·Journal for ImmunoTherapy of Cancer ·Joseph J. Sacco, Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari, Jessica C. Hassel, Alexandra P. Ikeguchi, Leonel F. Hernandez‐Aya, Paul Nathan, Omid Hamid, Josep M. Piulats, Matthew J. Rioth, Douglas B. Johnson, Jason J. Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, C. Holland, Takami Sato	13
2	Abstract A056: Development and application of an epithelial ovarian cancer-specific line of therapy algorithm using real-world data 2024 ·Cancer Research ·(unknown), (unknown), Sara Burns, (unknown), Matthew J. Rioth, Rayna K. Matsuno	1
3	Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer 2022 ·Clinical Lung Cancer ·Monika A. Izano, (unknown), Alan Fu, (unknown), (unknown), (unknown), Huakang Tu, (unknown), (unknown), Matthew J. Rioth, Thomas D. Brown	8
4	Machine learning application to find patients with lower-risk myelodysplastic syndrome from real-world data. 2022 ·Journal of Clinical Oncology ·Colden Johanson, Hu Huang, (unknown), (unknown), Matthew J. Rioth, Rayna K. Matsuno	2
5	Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts). 2021 ·Journal of Clinical Oncology ·Takami Sato, Richard D. Carvajal, Joseph J. Sacco, Alexander N. Shoushtari, Jessica C. Hassel, Alexandra P. Ikeguchi, Leonel F. Hernandez‐Aya, Paul Nathan, Matthew J. Rioth, Omid Hamid, Josep M. Piulats, Jason J. Luke, Douglas B. Johnson, Serge Leyvraz, Enrique Espinosa, Shaad E. Abdullah, (unknown), (unknown), Patricia Méndez, Marcus O. Butler	1
6	64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM) 2020 ·Annals of Oncology ·Joseph J. Sacco, Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari, Jessica C. Hassel, Alexandra P. Ikeguchi, Leonel F. Hernandez‐Aya, Paul Nathan, Omid Hamid, J.M. Piulats Rodriguez, Matthew J. Rioth, Douglas B. Johnson, Jason J. Luke, Enrique Espinosa, Serge Leyvraz, Howard Goodall, Christopher P. Holland, Shaad E. Abdullah, Takami Sato	24
7	Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy 2020 ·Cancers ·Carol M. Amato, Jennifer D. Hintzsche, Keith Wells, (unknown), Nicholas T. Gorden, (unknown), Richard P. Tobin, Kelsey W. Nassar, Yiqun G. Shellman, Jihye Kim, Theresa Medina, Matthew J. Rioth, Karl D. Lewis, Martin D. McCarter, René González, Aik Choon Tan, William A. Robinson	31
8	A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma 2020 ·Cancers ·(unknown), Matthew J. Rioth, Kari Kendra, Leonel F. Hernandez‐Aya, Richard W. Joseph, Stephen K. Williamson, Sunandana Chandra, Keisuke Shirai, Christopher D. Turner, Karl D. Lewis, Elizabeth Crowley, Jeffrey A. Moscow, Brett Carter, Sapna P. Patel	25
9	Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment 2019 ·Journal of the American Academy of Dermatology ·(unknown), Matthew J. Rioth, Megan Eguchi, Myles Cockburn	6
10	A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making 2019 ·Journal of Surgical Oncology ·Chloe Friedman, (unknown), Robert J. Torphy, (unknown), Patrick Hosokawa, René González, Karl D. Lewis, Theresa Medina, Matthew J. Rioth, William A. Robinson, Nicole Kounalakis, Martin D. McCarter, Ana Gleisner	21
11	SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care 2016 ·Journal of the American Medical Informatics Association ·Jeremy L. Warner, Matthew J. Rioth, Kenneth D. Mandl, Joshua C. Mandel, David Kreda, Isaac S. Kohane, (unknown), (unknown), Lucy Lu Wang, Shilin Zhu, Heming Yao, Gil Alterovitz	53
12	Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. 2016 ·Journal of Clinical Oncology ·Douglas B. Johnson, Garrett M. Frampton, Matthew J. Rioth, Erik Yusko, Riley Ennis, David Fabrizio, Joel Greenbowe, Siraj M. Ali, Dennie T. Frederick, Igor Puzanov, Justin M. Balko, Justin Cates, Jeffrey S. Ross, Harlan Robins, Vincent A. Miller, Phil Stephens, Ryan J. Sullivan, Jeffrey A. Sosman, Christine M. Lovly	12
13	Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology 2015 ·Bone Marrow Transplantation ·Matthew J. Rioth, Jeremy L. Warner, Bipin N. Savani, Madan Jagasia	11
14	Disparities in patient portal messaging by hematology and oncology patients. 2015 ·Journal of Clinical Oncology ·Matthew J. Rioth, Robert M. Cronin, Sharon E. Davis, Gretchen Purcell Jackson	1
15	Immune Checkpoint Inhibitors in NSCLC 2014 ·Current Treatment Options in Oncology ·Douglas B. Johnson, Matthew J. Rioth, Leora Horn	59
16	Incorporation of externally generated next-generation tumor genotyping into clinical and research workflows: Successes and lessons learned. 2014 ·Journal of Clinical Oncology ·Matthew J. Rioth, (unknown), Jeremy L. Warner	2
17	TORC1 Is Essential for NF1-Associated Malignancies 2008 ·Current Biology ·Cory M. Johannessen, Bryan W. Johnson, Sybil M. Genther Williams, Annie W. Chan, Elizabeth E. Reczek, Ryan C. Lynch, Matthew J. Rioth, Andrea I. McClatchey, Sandra Ryeom, Karen Cichowski	147
18	Targeted Deletion of the Calcineurin Inhibitor DSCR1 Suppresses Tumor Growth 2008 ·Cancer Cell ·Sandra Ryeom, Kwan‐Hyuck Baek, Matthew J. Rioth, Ryan C. Lynch, A. Zaslavsky, Amy E. Birsner, Sam S. Yoon, Frank McKeon	106
19	Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium 2008 ·Molecular Cancer Therapeutics ·Paul Beaudry, Monique B. Nilsson, Matthew J. Rioth, (unknown), (unknown), Lanwei Xu, Patrick A. Zweidler‐McKay, Anderson J. Ryan, Judah Folkman, Sandra Ryeom, John V. Heymach	38
20	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch 2006 ·Proceedings of the National Academy of Sciences ·Sylvie Giuriato, Sandra Ryeom, Alice C. Fan, Pavan Bachireddy, Ryan C. Lynch, Matthew J. Rioth, Jan van Riggelen, (unknown), Emmanuelle Passegué, Flora Tang, Judah Folkman, Dean W. Felsher	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact